Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 29.80
Bid: 29.00
Ask: 30.70
Change: -0.90 (-2.93%)
Spread: 1.70 (5.862%)
Open: 28.80
High: 29.80
Low: 28.80
Prev. Close: 30.70
EKF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DiaSpect Tm McKesson US distribution agreement

9 Aug 2018 07:00

RNS Number : 2695X
EKF Diagnostics Holdings PLC
09 August 2018
 

 

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

 

EKF Diagnostics Holdings plc

("EKF", the "Company")

 

DiaSpect Tm US distribution agreement with McKesson

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it has signed a private label distribution agreement with McKesson Medical-Surgical Inc., an affiliate of McKesson Corporation - the Fortune Global 500 healthcare distribution specialist and one of the largest companies in the US by revenue - for the Company's hand-held reagent-free hemoglobin analyzer, the DiaSpect Tm.

 

The DiaSpect Tm is the world's fastest hemoglobin analyzer and will be branded in the US by McKesson under its own branded line, as the McKesson Consult® Hb analyzer.

 

The agreement follows US Food and Drug Administration 510(k) clearance and CLIA waiver by statute for the DiaSpect Tm in April 2018, approving the product for use in point of care and Certificate of Waiver settings. Sales of the McKesson Consult® Hb analyzer are expected following full launch in the autumn, 2018.

 

For more information on the DiaSpect Tm see: www.ekfdiagnostics.com/diaspect.html 

 

Commenting, Julian Baines, CEO of EKF, said:  

"As I said in April the US market is a key target for the DiaSpect Tm, which gives physicians access to an easy to use, accurate and portable hemoglobin measurement system able to deliver laboratory quality results at the point of care within seconds." 

 

"This agreement with McKesson allows us to offer this innovative technology to physicians and childcare specialists across the US through the market's leading and most established healthcare distribution player. We expect that this partnership will ultimately deliver significant value to shareholders."

 

 

Enquiries:

 

EKF Diagnostics Holdings plc 

www.ekfdiagnostics.com

Christopher Mills, Non-Executive Chairman

Tel: 029 2071 0570

Julian Baines, CEO 

Richard Evans, FD & COO

N+1 Singer (Nomad & Broker)

Tel: 020 7496 3000

Aubrey Powell / Shaun Dobson

Walbrook PR Limited

Tel: 020 7933 8780 or ekf@walbrookpr.com

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

 

About McKesson Medical-Surgical mms.mckesson.com

McKesson Medical-Surgical Inc. is an affiliate of the McKesson Corporation. McKesson Corporation, currently ranked 6th on the FORTUNE 500, is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. McKesson Medical-Surgical works with health systems, physician offices, extended care providers, in-home patients, labs, payers and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting. McKesson Medical-Surgical helps its customers improve their financial, operational, and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services.

About EKF Diagnostics Holdings plc www.ekfdiagnostics.com

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRDDGDIRBGBGII
Date   Source Headline
4th Mar 20137:00 amRNSEstablishment of EKF Molecular & Acquisition
18th Jan 20137:00 amRNSPre-close Trading Update
21st Dec 20123:53 pmRNSDirectors' Exercise of Options
17th Dec 20127:00 amRNSHolding(s) in Company
27th Nov 20124:32 pmRNSHolding(s) in Company
9th Nov 20127:00 amRNSIssue of Equity
24th Sep 20127:00 amRNSHalf Yearly Report
5th Sep 20127:00 amRNSTrading Update
14th Aug 20127:00 amRNSNICE guidance on type 2 diabetes
10th Aug 20127:00 amRNSHemoCue settlement agreement
17th Jul 20127:00 amRNSLicensing agreement for kidney markers
16th Jul 20123:05 pmRNSHolding(s) in Company
16th Jul 20127:00 amRNSQuo-Lab CE marking & Commercial launch
12th Jul 20121:11 pmRNSHolding(s) in Company
28th Jun 20127:00 amRNSDirector's Share Options
26th Jun 201210:30 amRNSHolding(s) in Company
23rd May 20121:00 pmRNSResult of AGM
11th May 20127:00 amRNSUpdate on Disposal of IBL AG
20th Apr 201211:18 amRNSPublication of Annual Report & Notice of AGM
18th Apr 20124:50 pmRNSHolding(s) in Company
5th Apr 20127:00 amRNSDirectors' Exercise of Options
5th Apr 20127:00 amRNSChina Patent Grant
3rd Apr 20121:47 pmRNSHolding(s) in Company
27th Mar 20127:00 amRNSDisposal of International Brand Licensing AG
26th Mar 20128:18 amRNSAdviser Change of Name
21st Mar 20127:00 amRNSFinal Results
20th Mar 20127:00 amRNSAppointment of Group Head of Sales
16th Mar 20127:00 amRNSTrading Update & Notice of Final Results
8th Mar 20127:00 amRNSUS Patent Grant
6th Feb 20127:00 amRNSNew US contract win
30th Jan 20122:08 pmRNSHolding(s) in Company
19th Jan 20127:00 amRNSPre-Close Trading Update
30th Nov 20117:00 amRNSContract win
29th Nov 20117:00 amRNSUpdate on US market expansion
24th Oct 20115:53 pmRNSHolding(s) in Company
24th Oct 20115:51 pmRNSHolding(s) in Company
12th Oct 201112:42 pmRNSHolding(s) in Company
7th Oct 20113:44 pmRNSHolding(s) in Company
29th Sep 20115:14 pmRNSHolding(s) in Company
28th Sep 20117:01 amRNSDirectorate Change
28th Sep 20117:00 amRNSHalf Yearly Report
27th Sep 20117:00 amRNSChange of Adviser
23rd Sep 20111:26 pmRNSNotice of Results
6th Jul 20113:48 pmRNSResult of AGM
29th Jun 20119:45 amRNSDirectors' Dealings
22nd Jun 20117:00 amRNSHolding(s) in Company
20th Jun 201111:37 amRNSHolding(s) in Company
20th Jun 201111:35 amRNSHolding(s) in Company
17th Jun 20114:00 pmRNSHolding(s) in Company
16th Jun 20113:59 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.